secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034824
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B
-------------------------------------------------------------------------

- Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).
- Entered up to $2.1B asset purchase/license deal with Novo Nordisk for zaltenibart; $240M upfront at Q4 2025 close.
- Cash $36.1M at Sep 30; Q3 cash burn $22M ex-financing; raised $20.3M from Polar and $9M from ATM in Q3.
- PDUFA date for narsoplimab in TA-TMA extended to Dec 26, 2025; commercial launch team ready with brand YARTEMLEA.
- OMIDRIA royalties $9.2M in Q3 on net sales of $30.5M; operating expenses fell to $26.4M from $35.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/0001437749-25-034824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/omer20250825_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer